Immune Checkpoint Inhibitor-Related Pneumonitis
Abstract
Immune checkpoint inhibitors are novel agents that have been proved efficacious in a variety of cancer types, but they are associated with a unique set of organ-specific, immune-related adverse events. Among them, immune-related pneumonitis requires special attention because it is difficult to diagnose and potentially lethal. Accumulating real-world epidemiological data suggest that immune-related pneumonitis is more frequent than previously reported. Its diagnosis requires exclusion of other causes and assessment of radiographic features on high-resolution CT of the chest. Management of immune-related pneumonitis is based on the use of immunosuppressants. Future research should be focused on finding predictive biomarkers for immune-related pneumonitis as well as optimizing its management.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Drug-induced lung injury caused by ICIs worsens the prognosis of patients with NSCLC.
“Previous reports have shown that drug‑induced lung injury caused by ICIs worsens the prognosis of patients with NSCLC(30,31).”
From Clinical impact of inflammatory and nutrition index based on metabolic tumor activity in non‑small cell lung cancer treated with immunotherapy. (2024) · cites this paper as [31]
The citation lists haven’t been fetched yet
References 87 · Cited by 75
- Authors
- Gomatou, G., Tzilas, V., Kotteas, E., Syrigos, K., & Bouros, D.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- Venue
- Respiration
- Publisher
- S. Karger AG
- Published
- 2020
- Volume
- 99
- Issue
- 11
- Pages
- 932-942
- ISSN
- 0025-7931 (ISSN-L)
- 1423-0356
- OpenAlex
- W3108518804
- Cited by
- 75
- References
- 87
- Citations by year
- 2026: 14 · 2025: 16 · 2024: 13 · 2023: 15 · 2022: 16 · 2021: 1
- FWCI
- 0.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Respiration (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Epidemiology › Pneumonia and Respiratory Infections
- Keywords
- immune checkpoint inhibitors, immune-related pneumonitis, immune-related adverse events, immunosuppressive therapy, predictive biomarkers, high-resolution chest CT, cancer immunotherapy
- MeSH terms
- Nivolumab, Immune Checkpoint Inhibitors, Aged, Humans, Immunotherapy, Lung, Male, Neoplasms, Pneumonia, Risk Factors, Tomography, X-Ray Computed, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
